Buru Biosciences Secures Tens of Millions of RMB in Series A Funding to Advance Clinical Application of Breath-Based Diagnostic Platform for Infectious Diseases and Cancer

Recently, Shenzhen Burui Biotechnology Co., Ltd. (hereinafter referred to as “Burui Tech”) announced the completion of its Series A financing round, amounting to tens of millions of RMB.Led by Chunhua Ventures, with follow-on investment from Gaolue Capital. This round of funding will be used for itsThe World’s First “Human Exhaled Breath Detection Platform” Approved for Clinical ApplicationRegistration with the NMPA, clinical trials, and hospital market development and brand building for multi-disease diagnostic software and consumables. This financing marks another milestone for Burui Technology since its Pre-A round in 2021.

Burui Technology was established in December 2018 by a team comprising experienced business executives and young scientists. Within just three years, its flagship platform product, the "Mass Spectrometer for Human Exhaled Breath Analysis," has achieved rapid progress. Its efficacy in diagnosing infectious diseases and tumors has been preliminarily validated, with both the product and experimental data gaining recognition from multiple top-tier hospitals and experts. In 2021, the product received certification from the National Medical Products Administration (NMPA), marking it as the world’s first human breath analysis platform approved for clinical application in the field of breath testing.

Wang Dongjian, Founder of Burui Technology“It has been stated: ‘Precision, speed, simplicity, high throughput, low cost, and good patient compliance represent the unending pursuit of clinical diagnostics. The key factors enabling the productization and large-scale clinical adoption of breath testing solutions are their possession of these characteristics, which align closely with clinical testing needs. Now is the optimal time for the application of breath testing technology, as the underlying demand has always existed. Burui Technology has addressed the challenges of slow speed, high cost, low throughput, and complex operation associated with breath testing through a series of technological innovations, making true productization and large-scale clinical application possible. Currently, Burui Technology has completed the development and preliminary testing of multi-disease diagnostic software based on its breath testing platform in the fields of infection and oncology diagnosis. This round of financing will help Burui advance the NMPA registration, clinical trials, and market introduction of its product portfolio. We believe that with the support and assistance of capital market partners and clinicians, the Burui Technology team will surely achieve success for its products in both the Chinese and global markets, contributing Chinese solutions to the prevention and control of infectious diseases and cancer worldwide.”

Lead investor in this round,Zou Ling, Co-Head of Chunhua Venture Capital, stated“It is evident that breath testing is on the cusp of an industry boom. Its application in detecting tuberculosis and major respiratory infectious diseases has been widely validated, while its potential for early cancer screening has also garnered significant attention. Leveraging substantial market potential, Burui’s founding team has drawn upon its robust technical expertise and spirit of exploration to achieve industry-leading progress in R&D through sustained accumulation. We look forward to seeing Burui make even greater breakthroughs in the prevention and control of infectious diseases and tumors, and we are committed to providing strong support for the company’s development to benefit human health.”

Investors in this round,Mr. Li Jixiang, Founder of Gaolue Capitalstated: “Gaolue Capital remains firmly bullish on the investment outlook in the healthcare sector and continues to closely monitor industry transformations driven by medical technological innovations. Respiratory metabolomics has achieved a certain level of development and accumulation to date. Breakthroughs in detection technologies characterized by high precision, low cost, convenience, and speed can facilitate the clinical implementation of respiratory metabolomics, providing practical non-invasive screening and diagnostic solutions. Leveraging its independently developed single-photon ionization time-of-flight mass spectrometer, Burui Technology conducts detection and analysis of human exhaled breath, enabling early screening and diagnosis of malignant tumors and infectious diseases. The company has a clear development plan and a highly executable team. It designs and optimizes its product pipeline based on clinical needs, delivering excellent performance and promising market prospects both domestically and internationally.”

Primavera Venture Partners, an early-stage investment fund under Primavera Capital Group focused on frontier technology sectors, primarily invests in artificial intelligence and its related vertical applications, next-generation information technology, intelligent manufacturing, and medical technology. Its portfolio companies include Enflame Technology, Jian Shi Technology, Medtrum Technologies, BioAI, Calcite Tech, Xbiome, Zap Surgical, and Accession Therapeutics.

Chunhua Ventures aspires to partner with and support entrepreneurs who are genuinely driven by innovation and disruptive technologies. Leveraging our accumulated resources and investment ecosystem, we aim to empower technological breakthroughs that address the challenges facing humanity, thereby creating value for the sustainable development of the economy, society, and the environment.

Gaolue Capital is an emerging investment firm focused on the healthcare and next-generation information technology sectors. Adhering to the philosophy of value investing, the company follows a rigorous investment process and employs a research-driven strategy. It emphasizes deep professional understanding of industries, carefully selecting and curating high-quality projects with significant growth potential for investment, while striving to provide clients with value-added services throughout their entire lifecycle.